Veracyte, Inc. (VCYT)

Market Cap	3.04B
Revenue (ttm)	425.33M
Net Income (ttm)	-9.27M
Shares Out	77.50M
EPS (ttm)	-0.12
PE Ratio	n/a
Forward PE	43.22
Dividend	n/a
Ex-Dividend Date	n/a

Volume	815,105
Open	41.74
Previous Close	41.05
Day's Range	38.45 - 41.74
52-Week Range	18.61 - 47.32
Beta	1.71
Analysts	Buy
Price Target	40.86 (+4.29%)
Earnings Date	Feb 24, 2025

About VCYT

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis sy...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 30, 2013
• Employees: 815
• Stock Exchange: NASDAQ
• Ticker Symbol: VCYT
• Website: https://www.veracyte.com

Financial Performance

In 2023, Veracyte's revenue was $361.05 million, an increase of 21.76% compared to the previous year's $296.54 million. Losses were -$74.40 million, 103.5% more than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for VCYT stock is "Buy." The 12-month stock price forecast is $40.86, which is an increase of 4.29% from the latest price.

Price Target

$40.86

(4.29% upside)

Analyst Consensus: Buy